drugset / Trial / NCT04202549

Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)

NCT04202549

Completed 30 enrolled Huisheng Chen
NaSingle-groupOpen-labelTreatment

Summary

Thrombolysis and endovascular thrombectomy are the most efficient treatments for acute ischemic stroke patients in time window. Although sufficient recanalization after thrombectomy is more than 80%, HERMES study indicated that nearly half of the ischemic stroke patients under thrombectomy suffered obvious disability. Artery reocclusion, hemorrhagic transformation, and no-reflow phenomenon are among the most important reasons of poor prognosis of acute ischemic stroke patients. The investigators speculate that a combination of argatroban, edaravone, and glucocorticoid may be helpful in preventing artery reocclusion, hemorrhagic transformation, and no-reflow phenomenon. This study intends to explore the safety, feasibility and efficacy of thrombectomy with sufficient recanalization bridged by intra-arterial cocktail therapy in acute ischemic stroke patients.

Timeline

Start
2019-12-15
Primary completion
2022-09-20
Completion
2022-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Argatroban Small molecule 0.2 mg Other
Subject Argatroban Small molecule 0.3 mg Other
Subject Dexamethasone Small molecule 0.1 mg Other
Subject Edaravone Unknown 0.3 mg Other

Indications